167 related articles for article (PubMed ID: 28691327)
41. Cervical cancer in the human papillomavirus vaccination era.
Tay SK
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):3-7. PubMed ID: 22123221
[TBL] [Abstract][Full Text] [Related]
42. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
43. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
44. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
45. Singaporean women's knowledge of human papillomavirus (HPV) and attitudes toward HPV vaccination.
Pitts M; Smith A; Croy S; Lyons A; Ryall R; Garland S; Wong ML; Tay EH
Women Health; 2009 Jun; 49(4):334-51. PubMed ID: 19753508
[TBL] [Abstract][Full Text] [Related]
46. [Papillomavirus vaccines now allowed--ethical and logistical considerations].
Höpfl R
J Dtsch Dermatol Ges; 2007 May; 5(5):349-52. PubMed ID: 17451379
[No Abstract] [Full Text] [Related]
47. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
48. Rebuttal: Do you approve of spending $300 million on HPV vaccination? No.
Lippman A; Boscoe M; Scurfield C
Can Fam Physician; 2008 Mar; 54(3):343, 345. PubMed ID: 18337522
[No Abstract] [Full Text] [Related]
49. Women's knowledge of Pap smear test and human papillomavirus: acceptance of HPV vaccination to themselves and their daughters in an Islamic society.
Ilter E; Celik A; Haliloglu B; Unlugedik E; Midi A; Gunduz T; Ozekici U
Int J Gynecol Cancer; 2010 Aug; 20(6):1058-62. PubMed ID: 20683417
[TBL] [Abstract][Full Text] [Related]
50. Human papillomavirus-related content in state and tribal comprehensive cancer control plans.
Steele CB; Thomas CN; Richardson LC
J Womens Health (Larchmt); 2008; 17(1):5-10. PubMed ID: 18240976
[TBL] [Abstract][Full Text] [Related]
51. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine.
Tsai HJ
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):112-5. PubMed ID: 25951712
[TBL] [Abstract][Full Text] [Related]
52. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
53. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
54. Knowledge, attitudes, and practices among Saudi women regarding cervical cancer, human papillomavirus (HPV) and corresponding vaccine.
Jradi H; Bawazir A
Vaccine; 2019 Jan; 37(3):530-537. PubMed ID: 30503079
[TBL] [Abstract][Full Text] [Related]
55. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
56. [HPV vaccination and screening to eliminate cervical cancer. FIGO report].
Ginekol Pol; 2008 Jun; 79(6):445-6. PubMed ID: 18652135
[No Abstract] [Full Text] [Related]
57. Planning and advocating for cervical cancer prevention in Kebbi State, Nigeria: Learning points for the global call to eliminate cervical cancer.
Lawal IK; Suleiman AK; Bagudu Z; Kanmodi KK; Abdulsalam GA; Olakunle OS
Int J Gynaecol Obstet; 2021 Jan; 152(1):26-31. PubMed ID: 33034059
[TBL] [Abstract][Full Text] [Related]
58. Human papillomavirus and cervical cancer risk perception and vaccine acceptability among adolescent girls and young women in Durban, South Africa.
Russell VL; Ogilvie G; Beksinska M; Nyrenda M; Mitchell-Foster S; Lavoie J; Harder H; Wood B; Smith P; Dietrich JJ; Smit J; Brockman MA; Gray G; Kaida On Behalf Of The Ayazazi Research Team A
S Afr Med J; 2020 Aug; 110(9):887-893. PubMed ID: 32880274
[TBL] [Abstract][Full Text] [Related]
59. Prophylactic and therapeutic human papillomavirus vaccine: a breakthrough for women health.
Yousuf S; Syed S
J Pak Med Assoc; 2009 May; 59(5):310-4. PubMed ID: 19438137
[TBL] [Abstract][Full Text] [Related]
60. Greek health professionals' perceptions of the HPV vaccine, state policy recommendations and their own role with regards to communication of relevant health information.
Karamanidou C; Dimopoulos K
BMC Public Health; 2016 Jun; 16():467. PubMed ID: 27260348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
